Robert E. Wailes, MD

(Founder, Co-Owner and Medical Director)

Education & Training:

Undergraduate:	University of California, Berkeley
Medical School:	Wake Forest University School of Medicine, North Carolina
Postgraduate Training:	University of California, San Diego Anesthesia and Pain Management
Board Certifications:	American Board of Pain Medicine American Board of Anesthesiology with Subspecialty Certification in Pain Medicine
Additional Qualifications:	Qualified Medical Examiner, California Workers' Compensation Expert Reviewer, Medical Board of California Certified Supervisor Fluoroscopy Certification, State of California Advanced/Basic Cardiac Life Support Certified
Healthcare Leadership:	
	 President of the California Medical Association October 2021 to current President-elect of the California Medical Association 2020 to October 2021 Chairman of the CMA Board of Trustees, October 2017 to 2020 Vice-chair CMA Board of Trustees December 2014 to 2017 Trustee, representing San Diego, for the Board of Trustees for the California Medical Association, 2007 to 2012 and 2013 to 2020 President, San Diego County Medical Society 2011-12 Director, on the Board of Directors for the American Academy of Pain Medicine 2015 to present Delegate or Alternate Delegate to the AMA, representing Amer. Acad. of Pain Med. 2010-present Pain Medicine Representative to Informal Medicare Professional Advisory Council for Noridian 2010-present Board of Directors, CAL PAC 2008 to present Chairman Finance Committee, CMA Board of Trustees 2011 to 2018 Member, Technical Advisory Committee on Worker's Compensation for the California Medical Association, 01/08 to 01-2012 Member, Board of Directors, San Diego County Medical Society (SDCMS) 2004 to present
	Member, Executive Committee, SDCMS, 2006 to present Co-Chairman, Committee on Legislation, SDCMS, 2007 to present Program Director, Annual Pain Medicine Exposition, La Jolla, CA 1998 and Carlsbad, CA 1999, 2000, 2001, 2003 and 2004 Subsection Chief, Interventional Pain Medicine, Scripps Memorial Hospital, Encinitas, 01/04 to 10/11 Member, Board of Directors, North Coast Physician's IPA 1988-2000 President, Board of Directors, North Coast Physician's IPA 1993-1996 Member, Board of Directors, Hospice of the North Coast 1994-1999 Provider, Advanced Cardiac Life Support, 1980-presentAffiliate Faculty, Advanced Cardiac Life Support, 1987-89

 Specialized Training:
 MILD (Minimally Invasive Spinal Decompression)

 http://www.mildprocedure.com/

 Ultrasound for Treatment of Musculoskeletal Disorders

 Fluoroscopy Certification by California Department of Public Health

 Botox Therapies for Migraines and Spasticity

 Spinal Cord Stimulation

 Intrathecal Drug Delivery Systems

Research Publications:

Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study.

Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ; ONSTIM Investigators (**Robert Wailes**) Cephalalgia. 2011.Feb;31(3):271-85. PubMed PMID: 20861241. Article Link: <u>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057439/pdf/10.1177_0333102410381142.pdf</u>

Reliability and clinical utility of an implanted intraspinal catheter used in the treatment of spasticity and pain.

Krames E, Chapple I; 8703 W. Catheter Study Group. (**Robert Wailes**) Neuromodulation. 2000 Jan;3(1):7-14. PubMed PMID: 22151339. Article Link: <u>http://www.ncbi.nlm.nih.gov/pubmed/22151339</u>

Research Studies:

•

- SENSE[™] (Subcutaneous and Epidural Neuromodulation System Evaluation) Study (St. Jude) The SENSE[™] study is a prospective, multi-center, parallel design randomized, double-blinded study to demonstrate safety and efficacy of Peripheral Nerve field Stimulation (PNfS) and Spinal Cord Stimulation in combination with Peripheral Nerve field Stimulation (SCS-PNfS) using a St. Jude Medical Neuromodulation System. (<u>http://clinicaltrials.gov/ct2/show/NCT01990287?term=sense&rank=1</u>)
- Superion® ISISS Trial Protocol #08-VISS-01 (Vertiflex®) The Superion® InterSpinous Spacer (ISS) study is a prospective, multi-center, randomized controlled clinical trial comparing the Superion® ISS to the X-STOP® IPD® device in the treatment of subjects aged 45 or older suffering from moderate symptoms of neurogenic intermittent claudication secondary to a confirmed diagnosis of lumbar spinal stenosis (LSS) at one or two contiguous levels from L1 to L5.

(http://clinicaltrials.gov/ct2/show/NCT00692276?term=08-VISS-01&rank=1)

Medtronic Neuromodulation RestoreSensor[™] IDE Study (Protocol #1651) The RestoreSensor[™] Study is a prospective, multi-center, open-label, randomized crossover study to gather clinical information in subjects with and without the use of AdaptiveStim[™] feature of the RestoreSensor[™] Model 37714 implantable neurostimulator (INS) (http://clinicaltrials.gov/ct2/chow/NCT011064042torm=restoresensor%rapk=2

(http://clinicaltrials.gov/ct2/show/NCT01106404?term=restoresensor&rank=2)

 Occipital Nerve Stimulator (ONS) for the Treatment of Chronic Migraine Headache – Protocol #1602 (Medtronic)

The ONS study is a multicenter, randomized, blinded, controlled feasibility study was conducted to obtain preliminary safety and efficacy data on occipital nerve stimulation in chronic migraine.

(http://clinicaltrials.gov/ct2/show/NCT00200109?term=ons+1602&rank=2)

- Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain An Open-Label, Long-Term, Multi-Center, Intrathecal Ziconotide (PRIALT) Effectiveness and Safety Trial (ZEST) in Patients With Chronic Severe Pain (<u>http://clinicaltrials.gov/ct2/show/NCT00076544?term=zest&rank=5</u>)
- ConVERT Conversion to Embeda[®] with Rescue Trial Study (King Pharmaceuticals) Study designed to assess the success of converting opioid-experienced, moderate to severe chronic pain patients to a stable dose of EMBEDA[®] using a standardized conversion guide.

(http://clinicaltrials.gov/ct2/show/NCT01179191?term=convert+embeda&rank=1)

 Pharmacogenetic Saliva Study Assay Analysis (Protocol ML-001-2012) (Millennium Laboratories)

• Reliability and Clinical Utility of an Implanted Intrathecal Catheter Used in the Treatment of Spasticity and Pain (Poster) October 24, 1997- American Pain Society National Meeting, New Orleans

This is a 22-center study to examine the performance and reliability of a redesigned implantable

intrathecal catheter 8703W). (http://www.ncbi.nlm.nih.gov/pubme d/22151339)

- Study Efficacy of Matrix Spinal Cord Stimulation (post release from FDA) (multi-center)
- Intrathecal SNX-111 (Prialt) for Severe Chronic Pain (multi-center phase 3 clinical trials)
- Dextromethorphan vs. Morphine (multi-center clinical drug study)
- Oral Naloxone for Treatment of Severe Constipation (multi-center clinical drug study)
- An Open Label,Long-Term,Multi-Center,Intrathecal Ziconotide (Prialt)
- Trial for Refractory Headaches, 2007-9 (randomized, national multi-center study with new technology)

Professional Society Memberships:

American Academy of Pain Medicine North American Neuromodulation Society San Diego County Medical Society California Medical Association American Medical Association